Lipocine (LPCN) investor relations material

Key clinical results and analysis

• Phase III trial for postpartum depression treatment did not meet the primary endpoint, but showed rapid and significant efficacy in key subgroups, especially when excluding an outlier site.

• Excluding the anomalous site, results were statistically significant at all time points, with a treatment effect greater than -5 and rapid onset as early as 12 hours.

• Safety profile was highly favorable, with low rates of sedation and dizziness compared to the current standard of care, and no serious adverse events.

• Subgroup analysis demonstrated durable and clinically meaningful effects, with a median response time of 2.6 days and effect lasting one month.

• The anomalous site enrolled five times faster than others, had a disproportionate number of de novo patients, and showed implausibly high placebo response, raising concerns about data integrity.

Competitive landscape and differentiation

• The only approved competitor, ZURZUVAE, has an annualized run rate of $250 million and a peak potential over $1 billion.

• The new treatment offers a shorter regimen (2 days vs. 2 weeks), faster onset, and superior tolerability, with minimal sedation risk to both mother and infant.

• The product could meet FDA's rapid-acting antidepressant criteria, with efficacy demonstrated within one week and at-home administration.

Regulatory and financial outlook

• Applications for breakthrough and fast track designation have been submitted based on subgroup analysis.

• A guidance meeting with the FDA is planned to discuss excluding the outlier site and next steps; a new trial protocol is being prepared to avoid similar issues.

• Sufficient cash reserves ($25 million) are available to fund a new validation trial, with an expected burn rate of $1 million per month and interim results possible by late Q1 next year.

• If FDA agrees to exclude the outlier site, a new trial may not be necessary; preparations are underway for both scenarios.